Are there unmet needs in acid suppression?

Best Practice and Research: Clinical Gastroenterology

Volumn 18, Issue SUPPL., 2004, Pages 67-72

  Tytgat, G N J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Acid breakthrough; Acid inhibition; GERD, rebound hypersecretion; PPI

Indexed keywords

CYTOCHROME P450; ESOMEPRAZOLE; LANSOPRAZOLE; NON PRESCRIPTION DRUG; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ARTICLE; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MISUSE; ESOPHAGITIS; ESOPHAGUS DISEASE; FOOD DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; INTENSIVE CARE; INTERVIEW; METAPLASIA; PATIENT COMPLIANCE; PATIENT SATISFACTION; REBOUND; RELAPSE; STOMACH ACID SECRETION; STOMACH MUCOSA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTACIDS; ESOPHAGUS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; METAPLASIA; PROTON PUMPS; RECURRENCE; TREATMENT OUTCOME;

EID: 10644270665     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2004.06.014     Document Type: Article

References (17)

1. D.A. Revicki J.A. Crawley M.W. Zodet et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease Aliment Pharmacol Ther 13 1999 1621-1630
2. C.M. Bate S.M. Griffin P.W. Keeling et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis Aliment Pharmacol Ther 10 1996 547-555
3. T. Lind T. Havelund R. Carlsson et al. Heartburn without oesophagisits: efficacy of omeprazole therapy and features determining therapeutic response Scand J Gastroenterol 32 1997 974-979
4. R. Carlsson J. Dent R. Watts et al. Gastro-oeophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORD Study Group Eur J Gastroenterol Hepatol 10 1998 119-124
5. T. Lind T. Havelund R. Carlsson et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response Scand J Gastroenterol 32 1997 974-979
6. N.J. Talley K. Lauritsen H. Tunturi-Hihnala et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of on demand therapy for 6 months Aliment Pharmacol Ther 15 2001 347-354
7. D.O. Castell P.J. Kahrilas J.E. Richter et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis Am J Gastroenterol 97 2002 575-583
8. Malfertheiner P. Personal communication
9. M.F. Vaezi D.M. Hicks T.I. Abelson J.E. Richter Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): A critical assessment of cause and effect Clin Gastroenterol Hepatol 1 2003 333-344
10. D. Gillen K.E. McCol Problems related to acid rebound and tachyphylaxis Best Pract Res Clin Gastroenterol 15 2001 487-495
11. M. Weaver D.L. Patrick L.E. Markson et al. Issues in the measurement of satisfaction with treatment Am J Manag Care 3 1997 579-594
12. J.A. Crawley C.M. Schmitt How satisfied are chronic heartburn suffers with their prescription medications? Results of the patient unmet needs survey J Clin Outcomes Manag 7 2000 29-34
13. R. Shaker D.O. Castell P.S. Schoenfeld S.J. Spechler Nighttime heartburn is an under appreciated clinical problem that impacts sleep and daytime function: The result of a gallup survey conducted on behalf of the American Gastroenerological Association Am J Gastroenterol 98 2003 1487-1493
14. G.N.J. Tytgat Shortcomings of the first-generation proton pump inhibitors Eur J Gastroenterol Hepatol 13 2001 S29-S33
15. H.L. Waldum E. Breanna Personal review: Is profound acid inhibition safe? Aliment Pharmacol Ther 14 2000 15-22
16. N.D. Youmans J. Dent Personal review: Alarmism or legitimate concerns about long-term suppression of gastric acid secretion? Aliment Pharmacol Ther 14 2000 267-271
17. L. Laine D. Ahnen C. McClain et al. Review article: Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors Aliment Pharmacol Ther 14 2000 651-668